Aviado · Research
Longevity Daily
Wednesday, November 18, 2026
Listen
Today's Brief
Today's standout story: a repurposed erectile dysfunction drug called Mvix slowed Alzheimer's cognitive decline by nearly a third in a 1,500-person global trial — potentially the first oral therapy to meaningfully modify the disease's course. A 30-country study also challenges the assumption that all movement is brain-protective, finding leisure exercise helps while physically demanding work may actually raise dementia risk. Our Aviado analysis digs into green tea's EGCG and its dual enzyme-blocking action on blood sugar and fat absorption — a mechanism with real plausibility and honest caveats. The FDA's proposal to formally allow NAC in supplements rounds out an unusually consequential day for longevity science.
10 stories4 peer-reviewed2 trials1 Aviado original
Cognitive Health & Neuroprotection
A Viagra-Like Pill Slowed Alzheimer's Progression by Nearly a Third in a 1,500-Person Global Trial
A drug called Mvix — already sold in South Korea for erectile dysfunction — relaxes blood vessels and increases cerebral blood flow through a mechanism similar to Viagra, and it now appears to do something remarkable for the aging brain. In a year-long global trial of more than 1,500 people with early Alzheimer's, Mvix slowed cognitive decline by roughly a third compared to placebo, making it a candidate for the first oral pill to meaningfully modify the disease's course. There is a critical catch: benefits appeared only in patients not already taking other dementia medications, limiting its reach to earlier, unmedicated stages. If these results replicate, this low-cost repurposed drug could reshape how early Alzheimer's is treated — without the infusion-center burden of current antibody therapies.
Read more →Light-and-Sound Headset Shows Real Promise for Mild Alzheimer's — But Only for Early-Stage Patients
Cognito Therapeutics' 40-Hz device — which delivers flickering light and synchronized sound to entrain gamma brain waves linked to neural repair and reduced neuroinflammation — showed encouraging results in a trial of more than 600 participants followed for a year. The headset appeared to slow cognitive decline in those with mild Alzheimer's, though it missed its overall primary endpoint and showed no benefit for people with moderate cases. The findings suggest a viable non-drug, non-invasive pathway for early Alzheimer's, and MIT research suggests gamma-wave stimulation may also reduce amyloid accumulation over time.
Read more →Exercise Protects Your Brain — But Only If It's Not Your Job
Across a 30-country study, leisure-time physical activity consistently correlated with lower dementia risk, while physically demanding occupational work was associated with higher risk — a distinction that cuts against the simple 'move more, think better' message. The likely explanation: physical labor typically lacks recovery, produces chronic physiological stress, and misses the cognitive engagement that makes leisure exercise neurologically beneficial. If you're on your feet all day at work, intentional off-hours activity may still be essential for protecting your brain long-term.
Read more →Supplements & Compounds
Green Tea's EGCG Blocks Two Key Metabolic Enzymes — Here's What the Science Actually Says
EGCG, green tea extract's primary catechin, inhibits DPP-4 (a blood sugar-regulating enzyme in adipose tissue) and pancreatic lipase (a fat absorption enzyme in the gut) — a dual mechanism that could simultaneously blunt post-meal glucose spikes and reduce dietary fat uptake. Human trials support measurable metabolic improvements with standardized green tea extract at 200–400 mg EGCG daily, though direct enzyme-inhibition evidence in humans still leans heavily on cell and animal work. This Aviado analysis explains the mechanism clearly and is honest about what the clinical evidence can and cannot yet confirm — useful framing whether you track biomarkers or rely on symptoms and clinician guidance.
Read the full Aviado analysis →Taurine Could Be a Neuroprotective Supplement — But the Clinical Evidence Still Has Gaps
A new review in Mammalian Genome maps taurine's role in neuronal protection, cellular metabolism regulation, and suppression of biological processes linked to Alzheimer's and Parkinson's disease. Animal and cellular studies show genuinely promising results, but human clinical evidence remains inconclusive — and researchers dispute whether taurine levels reliably serve as a biomarker of brain aging. It's affordable and widely available, but it needs stronger human trial data before it earns a confident spot in a neuroprotection stack.
Read more →3 Popular 'Anti-Aging' Supplements That May Actually Be Working Against You
Beta-carotene heads the list — despite its antioxidant status, high-dose supplements have not been shown to protect against aging-related conditions and have been linked to elevated lung cancer risk in certain populations. The article also flags other widely-taken picks whose evidence trails far behind their marketing, and suggests better-supported alternatives for each category. A useful gut-check for anyone who has defaulted to antioxidant supplements without recently reviewing the data.
Read more →Research & Papers
A New Senolytic Vaccine Clears Zombie Cells and Rejuvenates Immune Function at the Same Time
Researchers have developed a senolytic vaccine that not only destroys senescent 'zombie' cells — the inflammatory byproduct linked to tissue damage and accelerated aging — but also restores dendritic cell function, addressing one of the immune system's core age-related deficits. In aging, the immune system progressively loses its ability to clear senescent cells while those same cells evolve immune-evasion strategies; a vaccine approach could disrupt both sides of that failure simultaneously. It is early-stage research, but the dual mechanism makes it one of the more conceptually compelling developments in the senolytic space.
Read more →Fat Cells Don't Just Store Energy — They Actively Spread Cellular Aging
Researchers identified asprosin — a protein secreted by fat cells — as a significant driver of cellular senescence, with levels markedly elevated in both senescent human endothelial cells and aging mice. Experiments using D-galactose-accelerated aging confirmed the link, and reducing asprosin activity slowed senescence-associated markers in mouse models. The finding reframes excess fat tissue not just as a metabolic risk but as a direct promoter of biological aging, and positions asprosin as a potential future target for senolytic or metabolic therapies.
Read more →Lifestyle & Nutrition
Even a Few Extra Minutes of Daily Movement Could Add Years to Your Life
Using new research on physical activity and longevity, the Washington Post built an interactive calculator translating incremental increases in daily movement into projected lifespan gains — and even modest additions register meaningfully. The underlying data reinforces that total daily movement volume, not exercise intensity, is the strongest modifiable predictor of lifespan for most people. It's a useful reality check: you don't need a structured training plan, you need consistency.
Read more →Industry & Policy
FDA Proposes Rule to Formally Allow NAC in Supplements — A First for the Industry
The FDA has proposed a rule that would officially classify N-acetylcysteine (NAC) as a legal dietary supplement ingredient, resolving years of regulatory ambiguity after NAC was affected by drug-preclusion rules. This marks the FDA's first use of new rulemaking authority under the supplement exclusion clause, with NAC becoming the inaugural ingredient listed under the new regulation. Industry associations have welcomed the move and are already pushing for the same process to cover other popular ingredients caught in the same regulatory gray zone.
Read more →